CN103356600A - Chukrasone B在抗幽门螺杆菌药物中的应用 - Google Patents
Chukrasone B在抗幽门螺杆菌药物中的应用 Download PDFInfo
- Publication number
- CN103356600A CN103356600A CN 201310279782 CN201310279782A CN103356600A CN 103356600 A CN103356600 A CN 103356600A CN 201310279782 CN201310279782 CN 201310279782 CN 201310279782 A CN201310279782 A CN 201310279782A CN 103356600 A CN103356600 A CN 103356600A
- Authority
- CN
- China
- Prior art keywords
- chukrasone
- helicobacter pylori
- medicines
- activity
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930187319 chukrasone Natural products 0.000 title claims abstract description 26
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims abstract description 11
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 6
- 241000590002 Helicobacter pylori Species 0.000 abstract description 16
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 208000007882 Gastritis Diseases 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001154 acute effect Effects 0.000 abstract description 5
- 208000023652 chronic gastritis Diseases 0.000 abstract description 5
- 208000000718 duodenal ulcer Diseases 0.000 abstract description 4
- 206010019375 Helicobacter infections Diseases 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 2
- 201000005917 gastric ulcer Diseases 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000002814 agar dilution Methods 0.000 description 4
- 241001156380 Chukrasia tabularis Species 0.000 description 3
- 108010087141 Kv1.2 Potassium Channel Proteins 0.000 description 3
- 102000006628 Kv1.2 Potassium Channel Human genes 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003450 potassium channel blocker Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108010040201 Polymyxins Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241001661641 Verrucosa Species 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310279782.2A CN103356600B (zh) | 2013-07-04 | 2013-07-04 | Chukrasone B在制备抗幽门螺杆菌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310279782.2A CN103356600B (zh) | 2013-07-04 | 2013-07-04 | Chukrasone B在制备抗幽门螺杆菌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103356600A true CN103356600A (zh) | 2013-10-23 |
CN103356600B CN103356600B (zh) | 2015-08-19 |
Family
ID=49359422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310279782.2A Active CN103356600B (zh) | 2013-07-04 | 2013-07-04 | Chukrasone B在制备抗幽门螺杆菌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103356600B (zh) |
-
2013
- 2013-07-04 CN CN201310279782.2A patent/CN103356600B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103356600B (zh) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102988355A (zh) | Aphanamixoid A在制备抗幽门螺杆菌药物中的应用 | |
CN111419829B (zh) | 和厚朴酚在抑制猪链球菌或其生物被膜中的用途 | |
CN102872132B (zh) | Houttuynoid D在抗幽门螺杆菌药物中的应用 | |
CN102861055B (zh) | Houttuynoid A在制备抗幽门螺杆菌药物中的应用 | |
CN102861067B (zh) | Houttuynoid E在制备抗幽门螺杆菌药物中的应用 | |
CN102872131B (zh) | Houttuynoid C在制备抗幽门螺杆菌药物中的应用 | |
CN102872154B (zh) | Houttuynoid B在抗幽门螺杆菌药物中的应用 | |
CN103550204A (zh) | Neonectrolide A在制备抗幽门螺杆菌药物中的应用 | |
CN103356600A (zh) | Chukrasone B在抗幽门螺杆菌药物中的应用 | |
CN103356608A (zh) | Fluevirosines A在制备抗幽门螺杆菌药物中的应用 | |
CN102885829A (zh) | Gypensapogenin B在抗幽门螺杆菌药物中的应用 | |
CN103381165A (zh) | Chukrasone A在抗幽门螺杆菌药物中的应用 | |
CN102872028B (zh) | Gypensapogenin A在抗幽门螺杆菌药物中的应用 | |
CN103446127B (zh) | Lycojaponicumin A在制备抗幽门螺杆菌药物中的应用 | |
CN103463023B (zh) | Lycojaponicumin B在制备抗幽门螺杆菌药物中的应用 | |
CN103446085B (zh) | Incarviatone A在制备抗幽门螺杆菌药物中的应用 | |
CN105535171A (zh) | 一种玫瑰花茶 | |
CN103690527B (zh) | Aphanamgrandiol A在制备抗幽门螺杆菌药物中的应用 | |
CN103120668A (zh) | Eryngiolide A在抗幽门螺杆菌药物中的应用 | |
CN103462979A (zh) | Spirooliganones B在制备抗幽门螺杆菌药物中的应用 | |
CN103479646A (zh) | Kadcoccitones A在制备抗幽门螺杆菌药物中的应用 | |
CN103251639A (zh) | Polyflavanostilbene A在制备抗幽门螺杆菌药物中的应用 | |
CN103446152A (zh) | Lycojaponicumin C在抗幽门螺杆菌药物中的应用 | |
CN103356633A (zh) | Aspeverin在制备抗幽门螺杆菌药物中的应用 | |
CN103599097A (zh) | Artoxanthochromane在抗幽门螺杆菌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171106 Address after: 401120 Chongqing Yubei District Food City Avenue 18 Chongqing advertising industrial park office space Patentee after: Chongqing San Mou science and Technology Development Co., Ltd. Address before: 210009 Gulou District, Jiangsu, Nanjing Gu Ping Kong, No. 4 Patentee before: Ding Shengyu |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200120 Address after: 211500 No. 59 Wang Qiao Road, Xiongzhou Street, Liuhe District, Nanjing City, Jiangsu Province Patentee after: Jiangsu Xiehe transformation Medical Research Institute Co., Ltd Address before: 401120 Chongqing Yubei District Food City Avenue 18 Chongqing advertising industrial park office space Patentee before: Chongqing San Mou science and Technology Development Co., Ltd. |